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Summary
We describe the heterologous expression in Escheri-
chia coli of the proenzyme precursor to EP-B2, a cyste-
ine endoprotease from germinating barley seeds. High
yields (50 mg/l) of recombinant proEP-B2 were
obtained from E. coli inclusion bodies in shake flask
cultures following purification and refolding. The
zymogen was rapidly autoactivated to its mature
form under acidic conditions at a rate independent of
proEP-B2 concentration, suggesting a cismechanism
of autoactivation. Mature EP-B2 was stable and active
over a wide pH range and efficiently hydrolyzed a
recombinant wheat gluten protein, a2-gliadin, at se-
quences with known immunotoxicity in celiac sprue
patients. The X-ray crystal structure of mature EP-B2
bound to leupeptin was solved to 2.2 A˚ resolution
and provided atomic insights into the observed
subsite specificity of the endoprotease. Our findings
suggest that orally administered proEP-B2 may be es-
pecially well suited for treatment of celiac sprue.
Introduction
Celiac sprue is a widespread but underdiagnosed auto-
immune type enteropathy of the small intestine that is
induced by the ingestion of gluten proteins found in
cereals such as wheat, rye, and barley. Genetically sus-
ceptible individuals develop an inflammatory response
to proteolytically resistant, proline- and glutamine-rich
epitopes in gluten, resulting in villous atrophy, crypt
hyperplasia, and malabsorption of nutrients [1, 2]. The
only effective treatment currently available to a patient
*Correspondence: khosla@stanford.eduis strict dietary exclusion of gluten-containing products.
Several recent studies have highlighted the therapeutic
potential of orally administered prolyl endopeptidases
(PEPs), a family of enzymes with the unique ability to
cleave at internal Pro residues in proteolytically resistant
gluten epitopes [3–8]. However, the effectiveness of
these enzymes may be limited by their substrate chain
length restrictions [9, 10] and by the fact that they act
at the relatively neutral pH of the small intestine, where
undigested peptides can simultaneously access the
gut-associated lymphoid tissue underlying the intestinal
mucosal epithelium. As gluten is comprised of w35%
Gln, a residue that is not a preferred cleavage site for
any pancreatic endoprotease, the digestive efficacy of
PEPs could be enhanced by coadministration of a Gln-
specific endoprotease, particularly if this endoprotease
is active upstream of the intestine in the acidic stomach.
Here, we describe the heterologous expression, purifi-
cation, refolding, and structural-functional characteriza-
tion of a candidate enzyme that fulfills these criteria, the
barley cysteine endoprotease, EP-B2.
Our choice of barley (Hordeum vulgare) EP-B2 was
influenced by the evolutionary argument that nature
may have evolved this enzyme to incorporate many de-
sirable characteristics of an oral therapeutic agent that
breaks down dietary gluten in the stomach and upper
small intestine. EP-B2 is secreted as a proenzyme
(proEP-B2) into the acidic endosperm of germinating
barley seeds, where it is activated to its mature form.
Its physiological substrates are Pro- and Gln-rich hor-
deins, which are major storage proteins in barley gluten
[11–13]. Substrate specificity analysis of EP-B2 purified
from green malt barley suggested that EP-B2 cleaves
preferentially after Gln residues, often with Pro at the
P2 position [14]. However, biochemical studies per-
formed to date have utilized EP-B2 from the natural
source (germinating barley seeds), which places intrin-
sic limits on further enzymological, pharmacological,
and protein engineering studies. We therefore sought
to produce the proenzyme as a recombinant protein in
E. coli and to characterize its folded form and activation
mechanism as well as the structure, activity, and speci-
ficity of the mature enzyme. The results of our studies
are reported here.
Results and Discussion
Heterologous Expression and Purification
of Recombinant ProEP-B2
Native EP-B2 is synthesized in the aleurone layer of ger-
minating barley seeds as a 43 kDa preproenzyme, pos-
sessing a signal sequence that directs the secretion of
the proenzyme and is subsequently removed, as well
as an N-terminal propeptide that renders proEP-B2
stable and inactive [12]. Previous attempts to express
papain-like cysteine proteases in heterologous systems
have shown that the signal sequence must be removed
prior to heterologous expression [15] and that the pro-
peptide must be retained for proper folding and stability
[16–19]. By expressing a truncated form of the EPB2
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638Figure 1. Purification and Sequence of
Recombinant ProEP-B2
(A) SDS-PAGE analysis of NiNTA column pu-
rification of proEP-B2. Lanes: molecular
weight markers (M); resolubilized inclusion
bodies (1); NiNTA column flowthrough (2);
NiNTA column wash (3); NiNTA column elu-
ate (4); and mature EP-B2 following proEP-
B2 purification, refolding, and activation at
pH 4.5 (5).
(B) Sequence of recombinant proEP-B2.
Recombinant proEP-B2 is 43.7 kDa. Plasmid
contributions are in bold; residues altered by
primer-directed mutagenesis for cloning are
underlined. Mature EP-B2 is 27.7 kDa. The
N terminus of mature EP-B2 (;) was deter-
mined by N-terminal sequencing.gene lacking its signal sequence, an expression level of
50 mg of recombinant, His6-tagged proEP-B2 per liter of
E. coli culture was achieved. The majority of this poly-
peptide was recovered in the pellet from high-
speed centrifugation of the cell lysate, suggesting that
proEP-B2 was expressed predominantly in inclusion
bodies. This is a common fate for papain-like cysteine
endoproteases expressed in heterologous hosts [20].
Following denaturing nickel-nitriloacetic acid (Ni-NTA)
affinity chromatography, a single major band eluted
from the column at w45 kDa with a purity of >90%, as
assessed by SDS-PAGE (Figure 1A). This is in good
agreement with the predicted molecular weight
(43.7 kDa) of recombinant proEP-B2 based on its se-
quence (Figure 1B).
The purified material was refolded by rapid dilution
into a refolding buffer at pH 8.0, yielding folded proEP-
B2, as measured by its ability to self-activate into a single
30 kDa product under acidic conditions (Figure 1A, lane
5). N-terminal sequencing of this product revealed that it
corresponded to a 27.7 kDa mature EP-B2 protein (Fig-
ure 1B). The N terminus of this recombinant mature
enzyme includes a two-residue extension compared to
the naturally derived mature enzyme [12], a feature
that has precedence in the context of other recombinant
cysteine endoproteases activated in vitro [20].
Crystallization and Structure Determination
of Mature EP-B2 Bound to Leupeptin
To provide a structural basis for the mechanism of
activation of EP-B2 and its hydrolytic activity toward
specific peptide sequences, we solved the X-ray crystal
structure of EP-B2 complexed with the peptidic cysteine
protease inhibitor, leupeptin. Following activation of
proEP-B2 to its mature form and covalent inhibition
with leupeptin, the EP-B2-leupeptin complex was puri-
fied by FPLC and crystallized by hanging drop vapor
diffusion. The complex crystallized in the space group
P1 with four covalently inhibited EP-B2 monomers per
asymmetric unit. The crystal structure was solved by
molecular replacement and refined to 2.2 A˚ resolution
with R and Rfree values of 20.3% and 23.3%, respec-
tively. Data, refinement, and model statistics are shown
in Table S1 (see the Supplemental Data available with
this article online).
The overall structure of mature EP-B2 consists of two
comparably sized domains, canonically designated Rand L, which are divided by the active site cleft (Fig-
ure 2A). Numbering from the N terminus of the mature
recombinant enzyme (Figure 1B), domain R is primarily
composed of an extended N-terminal loop (residues 3–
23) and four antiparallel b sheets (residues 121–223),
while the predominantly a-helical domain L comprises
residues 24–120 and the observed C-terminal residues
224–226. Three conserved disulfide bonds (Cys25-
Cys67, Cys59-Cys100, Cys161-Cys213) further stabilize
EP-B2’s tertiary structure, which shares a high degree of
similarity to previously determined structures of related
cysteine endoproteases (Figure 2B). Residues 1–2 and
227–262 of the mature enzyme are not well defined by
the electron density and are not included in the refined
model.
The active site of EP-B2 is located within an w10 A˚
deep groove that spans the junction between the R
and L domains (Figure 2C). The main chain of leupeptin
is bound along the length of this groove by two hydrogen
bonds between Gly70 and the P2 position backbone
atoms of the substrate and by a third hydrogen bond
between Asp166 and the P1 position backbone. These
interactions serve to position the C-terminal aldehyde
of leupeptin proximal to the Cys28 thiolate. The side
chain of Gln22 and the main chain nitrogen atoms of
Ser27 and Cys28 comprise the oxyanion hole, which sta-
bilizes the negative charge buildup on the carbonyl oxy-
gen of the substrate upon Cys28-mediated nucleophilic
attack. As in other cysteine proteases, the nucleophilic-
ity of the catalytic cysteine is enhanced by His167-medi-
ated proton abstraction (sulfur to nitrogen distance =
3.7 A˚). The amide oxygen of the conserved Asn188
side chain orients His167 for proton abstraction from
Cys28 (O-N distance = 2.9 A˚), thus completing the cata-
lytic triad (Figure 2D).
The substrate specificity of cysteine endoproteases is
substantially influenced by enzyme interactions with
substrate residues beyond those P1 and P10 residues
flanking the scissile bond (e.g., substrate residues in
contact with the S3–S20 subsites) [26]. Leupeptin, a tri-
peptide cysteine protease inhibitor, occupies the S3–
S1 subsites of EP-B2, allowing for identification of those
enzyme residues that participate in binding substrate
residues located N-terminal to the site of cleavage (Fig-
ures 2C and 2E). In contrast to the related cysteine endo-
protease, papain, where two tyrosine residues restrict
the size of P3 side chains [26, 27] (Figure 2E), the S3
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639Figure 2. Crystal Structure of Mature EP-B2 Complexed with Leupeptin
(A) Ribbon diagram of EP-B2 monomer bound to leupeptin (acetyl-Leu-Leu-Arg-al). Color-coding of EP-B2 is according to primary sequence,
from blue (N terminus) to red (C terminus); inhibitor is shown in green in stick representation. Orientation is the standard view for cysteine
endoproteases, with the R domain at right, the L domain at left, and the active site at top.
(B) Ca alignment of EP-B2 (green; PDB ID: 2FO5) with CysEP (teal; PDB ID: 1S4V) [21], papain (orange; PDB ID: 1STF) [22], and GP-II (magenta;
PDB ID: 1CQD) [23]. Modifications to active-site cysteines in structures other than EP-B2 have been removed for clarity.
(C) Molecular surface depiction of the EP-B2 active site cleft (top view). The EP-B2 surface is colored according to electrostatic potential (blue,
positive; red, negative; white, neutral); inhibitor in green. Potential values shown are in the range of 225 kBT to +25 kBT. Electrostatic potential
was calculated with the program APBS [24].
(D) Active site of EP-B2 (top view). Catalytic triad residues (Cys28, His167, and Asn 188) are colored and labeled in purple. Main chains and
side chains of EP-B2 residues forming polar contacts with leupeptin (red dashed lines) are shown and are labeled in red. Inhibitor is in gray.
(E and F) Alignment of cysteine endoprotease structures from (B) (same coloring and modifications for clarity) emphasizing those residues
comprising the S2–S1 (E) and the expected S10–S20 (F) subsites. Residue labels are colored in correspondence to the structural coloration.
All figure panels were prepared with the molecular graphics program PyMOL [25].subsite of EP-B2 features Asp65 and Leu71 at the corre-
sponding positions, thereby yielding a markedly more
open pocket. Residues Gly69 and Gly70 lie at the base
of this pocket. In addition, the carbonyl oxygen of
Asp63 provides the potential for hydrogen bonding
with the substrate. The S2 subsite is usually the deepest
pocket in cysteine endoproteases [21, 26–28]. In EP-B2,
this pocket is lined by predominantly hydrophobic resi-
dues, including Leu71, Met72, Ala141, and Leu165, but
has the anionic Glu218 residue at its base. As in CysEP
[21], the presence of residue Leu71 in place of bulkieraromatic residues, found in many other cysteine endo-
proteases (e.g.,Trp in GP-II, Tyr in papain), renders this
pocket substantially wider in EP-B2. Finally, the S1 sub-
site consists of a shallow depression between Gly26
and Gly69 as well as the carbonyl oxygen of Cys65,
which is presumably available for hydrogen bonding.
In papain and R. communis CysEP, an Asn residue
may additionally interact with the P1 side chain of long
polar residues, but the orientation of the corresponding
EP-B2 residue, Gln68, renders this interaction unlikely in
EP-B2.
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640Figure 3. Activation of ProEP-B2 to Mature EP-B2
(A) Time course of proEP-B2 activation. One milligram per milliliter (w23 mM) proEP-B2 was activated for 0–120 min at pH 4.5, 25ºC, and the
extent of activation was analyzed by SDS-PAGE. Molecular weight markers (M). Results are typical of more than five similar experiments.
(B) Concentration dependence of proEP-B2 activation. 0.5–8 mM proEP-B2 was preincubated at pH 3.0, 25ºC, for the specified duration, and
then chromogenic substrate Z-FR-pNA was added to a final concentration of 50 mM. In the process, a 5-fold dilution of the protein occurs
(corresponding to 0.1–1.6 mM preincubated proEP-B2). The reaction rate was measured from the initial slope of the A410 versus time plots
and converted to Vo in mM/min with 3410 = 8,800 M
21cm21 for pNA.Although the lack of inhibitor residues C terminal to
the aldehyde functional group precludes definitive defi-
nition of individual subsites in the S0 region of EP-B2,
several general observations can be made. First, the S0
region of the active site is wider and less polar than
the S region (Figure 2C). Additionally, the identity and
orientation of those residues that presumably define
the S10 and S20 subsites in EP-B2, defined by analogy
to the solved structure of cathepsin B with an epoxysuc-
cinyl-based inhibitor bound to its S0 region [29], are strik-
ingly more conserved than those comprising the corre-
sponding S region (Figures 2E and 2F). Together, these
points suggest that the S region of the active site cleft
plays a more important role than the S0 region in deter-
mining EP-B2 specificity, though residues in this latter
region may contribute as well.
Kinetics of Activation of ProEP-B2 to Mature EP-B2
In a germinating barley seed, activation of proEP-B2
proceeds through a series of posttranslational process-
ing steps to yield the mature enzyme capable of cleaving
hordeins and other cereal storage proteins [12]. Since
related cysteine endoproteases autoactivate to their
mature forms in vitro when introduced into an acidic en-
vironment [30, 31], we sought to determine whether re-
combinant proEP-B2 can be autocatalytically activated
to its mature form under analogous conditions. Re-
combinant proEP-B2 was therefore incubated in a pH
4.5 buffer, a pH value at which activity of barley-derived
EP-B2 has been reported [28]. The extent of activation
as a function of time was analyzed by SDS-PAGE. As
shown in Figure 3A, under these conditions, proEP-B2
was almost completely activated to its mature form
within 15 min, and the full-length proenzyme disap-
peared by the earliest time point measured (2 min). Inter-
estingly, a series of intermediates are observed between
2–5 min, suggesting that autoactivation involves pro-
peptide cleavage at multiple sites. Similar results were
observed in a pH 3.0 buffer (data not shown), highlight-
ing the pharmacological potential for autoactivation of
EP-B2 in the acidic stomach. In further support of the
hypothesis that proEP-B2 activation is autocatalytic innature, equimolar addition of leupeptin completely
blocked activation over a similar time course (data not
shown).
Autoactivation of proEP-B2 can proceed through two
nonexclusive mechanisms, cis and trans activation. If
cis activation predominates, activation occurs through
intramolecular cleavage(s), and the rate of activation
should be independent of proEP-B2 concentration. In
contrast, if trans activation predominates, the rate of ac-
tivation should increase with proEP-B2 concentration.
We therefore preincubated proEP-B2 at varying concen-
trations in a pH 3.0 buffer. At each concentration, the
chromogenic substrate Z-FR-pNA was added at various
time points and enzyme activity was measured. As
shown in Figure 3B, the enzymatic activity measured im-
mediately upon addition of proEP-B2 (0 min time point)
in each curve is proportional to the proEP-B2 concentra-
tion in that reaction mixture, suggesting that the rate
of proEP-B2 activation is first order with respect to
proEP-B2 concentration. Furthermore, the time taken
to reach maximum enzyme activity at each proEP-B2
concentration is also independent of proEP-B2 concen-
tration. Together, these observations suggest that
proEP-B2 activation occurs primarily via a cis intra-
molecular cleavage mechanism, a feature that is well
suited for in situ gastric activation of orally administered
proEP-B2 and a mechanism of activation that was not
revealed by the previous heterologous expression of
EP-B2 in Trichoderma reesei [32–34].
Although the above kinetic data support intramolecu-
lar activation, the distance between the N terminus of
the mature enzyme and the active site is w30 A˚ (Fig-
ure 2A), suggesting that the cleavage of the peptide
bond between the propeptide region and the mature
enzyme is intermolecular. We therefore propose a two-
step activation mechanism, in which intramolecular
activation under acidic conditions is followed by a faster
intermolecular cleavage reaction. Such a model is sup-
ported by the structures of the zymogen [35] and mature
[36] forms of the closely related cysteine endoprotease
cathepsin L, as well as related mechanistic observations
[37, 38].
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ProEP-B2 and Mature EP-B2 to Pepsin and
Trypsin
(A) Pepsin (0.5 mg/ml) was incubated at pH
3.0 with 0.5 mg/ml proEP-B2 or mature
EP-B2 in the presence of 100 M equivalents
of leupeptin. At designated time points, the
reaction was quenched and the digestion
products were loaded on SDS-PAGE. Molec-
ular weight markers (M).
(B) Trypsin (0.5 mg/ml) was incubated at pH
6.0 with 0.5 mg/ml proEP-B2 or mature, inac-
tivated EP-B2, and the reaction progress
was monitored by SDS-PAGE. Results are
typical of two similar experiments.In addition to providing insight into the mechanism of
proEP-B2 activation, the data in Figure 3B also suggest
that mature EP-B2 inactivates slowly, presumably via
autolysis at pH 3.0. This is confirmed by SDS-PAGE
analysis and can be attenuated in the presence of other
preferred substrates of EP-B2 such as gliadins (data not
shown).
Comparison of ProEP-B2 and EP-B2 Susceptibility
to Pepsin and Trypsin
The therapeutic utility of EP-B2 for celiac sprue would
be substantially influenced by its sensitivity to the major
proteases of the gastrointestinal tract, pepsin in the
stomach, and trypsin and chymotrypsin in the small in-
testine. We therefore incubated both proEP-B2 and
EP-B2 with either pepsin (at pH 3.0) or trypsin and chy-
motrypsin (at pH 6.0) and analyzed the reaction mixtures
by SDS-PAGE. Leupeptin was added to reactions per-
formed at pH 3.0 to prevent self-processing of proEP-
B2 to its mature form. In the presence of an equivalent
amount of pepsin, mature EP-B2 was highly resistant
to proteolysis over a 60 min incubation period (Fig-
ure 4A). Pepsin rapidly digested the propeptide region
of proEP-B2 but left intact a stable band corresponding
to the size of the mature enzyme. In contrast, mature EP-
B2 is susceptible to physiological concentrations (0.5
mg/ml) of trypsin with a half-life ofw15 min (Figure 4B)
but is resistant to comparable concentrations of chymo-
trypsin (data not shown). Thus, EP-B2 can be expected
to remain active during the gastric phase of gluten di-
gestion but be rapidly broken down in the duodenum.
If necessary for its therapeutic application, the intestinal
stability of recombinant EP-B2 could be increased
through structure-guided modification of susceptible
trypsin cleavage sites.pH Dependence of ProEP-B2 Activation and Mature
EP-B2 Activity
For orally administered proEP-B2 to effectively break
down dietary gluten in the upper gastrointestinal tract,
it must be activated in the acidic environment (pH 2–3)
of a fasted stomach and retain high activity in the weakly
acidic pH range of the postprandial stomach and duode-
num (pH 3–7) [39]. We therefore investigated the pH de-
pendence of zymogen activation as well as of mature
EP-B2 activity. When recombinant proEP-B2 was added
to Z-FR-pNA in a series of citrate-phosphate buffers
ranging from pH 2.3–6.9, the enzyme activity was appar-
ently optimal at pH 4.5 (Figure 5). This observation is
consistent with the reported pH optimum of 4.0 deter-
mined for the native proenzyme from barley [28] and rep-
resents a composite pH optimum for the dual processes
of autoactivation of proEP-B2 to mature EP-B2, as well
as the catalytic activity of mature EP-B2 against the
chromogenic substrate. To determine the pH optimum
of each process separately, two additional experiments
were performed. First, the pH optimum of proEP-B2 ac-
tivation was determined by preincubating proEP-B2
over a range of pH values (2.3–6.9) for 30 min, followed
by measurement of Z-FR-pNA turnover at pH 6.0. In sep-
arate experiments, it was determined that at pH 6.0 ma-
ture EP-B2 is active, but no further activation of proEP-
B2 will occur. The reaction rate in each sample therefore
corresponds to the amount of mature enzyme produced
during preincubation under a given pH regime. In the
second experiment, the pH optimum of EP-B2 activity
was determined by completely activating proEP-B2 at
a constant pH of 4.5, followed by measurement of its ac-
tivity against Z-FR-pNA across a range of pH values.
Here, all reactions began with the same amount of active
EP-B2, so differences in rates between reactions were
Chemistry & Biology
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EP-B2. As shown in Figure 5, activation of proEP-B2 oc-
curs most efficiently below pH 4.0, but, once activated,
the specific activity of mature EP-B2 increases with
increasing pH up to pH 7.0. These separate pH optima
account for the apparent pH optimum of 4.5 for the com-
bined processes.
In addition to providing new insight into this cysteine
protease’s remarkable pH dependence, this finding has
therapeutic ramifications for celiac sprue. When admin-
istered orally into the prefed stomach, proEP-B2 should
activate rapidly and then catalyze the breakdown of any
dietary gluten that enters the stomach with the meal. Its
extreme resistance to pepsin would enable it to survive
Figure 5. pH Optimum of ProEP-B2 Activation and EP-B2 Activity
To measure pH dependence of autoactivation, proEP-B2 was pre-
incubated 30 min at pH 2.3–6.9 and then assayed at pH 6.0 (A),
a pH value at which autoactivation does not occur to an apprecia-
ble extent. To measure pH dependence of mature EP-B2 activity,
proEP-B2 was fully activated at pH 4.5 for 60 min and then assayed
at pH 2.3–6.9 (-). The composite effect of pH on proenzyme acti-
vation and enzyme activity is also shown (6), where substrate was
added directly to proEP-B2 at pH 2.3–6.9. ProEP-B2 concentration
was 400 nM in all reactions, and 50 mM Z-FR-pNA was used.
Vo was calculated as described in Experimental Procedures.throughout the residence time of food in the stomach
and even continue cleaving residual gluten peptides
when the food is emptied in the duodenum. Eventually,
EP-B2 will be deactivated by trypsin proteolysis.
Activity of EP-B2 against More Complex Substrates
Although the precise mechanisms underlying celiac
sprue pathogenesis remain to be fully elucidated, there
exists much evidence that two attributes of gluten pep-
tides contribute to their antigenic potential: their proteo-
lytic resistance [3–5, 10] and their deamidation at
selected Gln residues by human transglutaminase 2 [4,
40–45]. Therefore, for barley EP-B2 to accelerate gastro-
intestinal gluten detoxification, it must have comple-
mentary specificity to endogenous proteases. In partic-
ular, since neither pepsin nor the pancreatic proteases
recognize Gln as a preferred cleavage site (although
chymotrypsin has low specificity for Gln), we were
intrigued by the possibility that EP-B2 could fulfill this
role. To analyze the subsite bias of EP-B2 in the context
of representative gluten peptides and proteins, we used
two substrates—a Pro- and Gln-rich highly antigenic
33-mer peptide [4] and recombinant a2-gliadin [46],
the gluten protein from which this peptide is derived.
The 33-mer peptide, LQLQPFPQPQLPYPQPQLPYPQ
PQLPYPQPQPF, bearing six copies of three immunodo-
minant epitopes, was tested because its pharmacologi-
cal relevance and repetitive sequence make it an ideal
target for initial efficacy studies. Incubation of the 33-
mer peptide with catalytic amounts of proEP-B2 (1:10
molar ratio, enz:sub) at pH 3.0 for 60 min resulted in sub-
stantial breakdown of the peptide (Figure 6A), although
the peptide was stable under similar conditions without
enzyme added (data not shown). Three major proteolytic
fragments were observed by LC-MS/MS analysis (Fig-
ure 6B) that collectively identified four cleavage sites
within the 33-mer peptide (Figure 6C). Interestingly, the
P1 positions of three of these cleavage sites correspondFigure 6. Activity of EP-B2 against the Proteolytically Resistant 33-mer Peptide from a2-Gliadin
(A) RP-HPLC UV215 traces of the intact synthetic 33-mer and of 33-mer following 60 min of digestion by EP-B2 at a molar ratio of 1:10 pro-
enzyme:substrate (pH 3.0).
(B) LC-MS mass chromatogram of the digested sample from (A). Peaks labeled as digestion fragments were identified by their MS2 spectra.
(C) Sequence of the 33-mer peptide showing sites of EP-B2 catalyzed cleavage (Y), as determined by LC-MS/MS.
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643Figure 7. Specificity of EP-B2-Catalyzed
Cleavage of the Recombinant Gluten Pro-
tein, a2-Gliadin
(A) Time course of a2-gliadin digestion at pH
3.0. ProEP-B2 was added to a2-gliadin at
a molar ratio of 1:10 proenzyme:substrate
at pH 3.0, and the reaction was allowed to
proceed for 60 min. At the indicated times,
the reaction was sampled, quenched, and
the digestion products were analyzed via
SDS-PAGE. Molecular weight markers (M).
Results are typical of more than five similar
experiments.
(B) Sequence of a2-gliadin showing sites of
cleavage as determined by LC-MS/MS
following 5 min (;) or >15 min (Y) incubation
with proEP-B2 at a molar ratio of 1:10 pro-
enzyme:substrate (pH 3.0). The sequence
corresponding to the 33-mer peptide is
underlined.
(C) As in (A), but the digestion was per-
formed at pH 4.5.
(D) As in (B), but from pH 4.5 digestion.
(E) Time course of equine skeletal muscle
myoglobin digestion at pH 4.5. ProEP-B2
was added to myoglobin at a molar ratio of
1:10 proenzyme:substrate at pH 4.5, and
the reaction was allowed to proceed for
60 min. At the indicated times, the reaction
was sampled, quenched, and the digestion
products were analyzed via SDS-PAGE.
(F) Sequence of myoglobin showing sites of
cleavage as determined by LC-MS/MS fol-
lowing 5 min (;) or >15 min (Y) incubation
with proEP-B2 at a molar ratio of 1:10 proen-
zyme:substrate (pH 4.5).to the primary sites of transglutaminase-mediated in vi-
tro deamidation of this antigenic peptide [4]. Extensive
analysis of the epitope sequences within the 33-mer
peptide [40] indicates that the observed EP-B2 cata-
lyzed proteolytic pattern should result in complete elim-
ination of its inflammatory potential.
Notwithstanding these encouraging results, the ob-
served cleavage sites in the 33-mer peptide provide lim-
ited information regarding EP-B2 specificity, since al-
most all peptide bonds in this sequence contain
a typically disfavored Pro residue in the P1 or P10 posi-
tions [28]. To obtain more extensive and pharmacologi-
cally relevant insight into the specificity of recombinant
EP-B2, catalytic amounts (1:10 molar ratio) of proEP-B2
were incubated with recombinanta2-gliadin, a represen-
tative wheat gluten protein, at both pH 3.0 and pH 4.5. At
specified time points, the reaction mixture was analyzed
by SDS-PAGE or by LC-MS/MS. As shown in Figure 7A,
proEP-B2 was able to completely and rapidly hydrolyze
a2-gliadin into small peptide fragments at pH 3.0, al-
though the protein was stable under similar conditions
in the absence of proEP-B2 (data not shown). Most of
these fragments were identified by LC-MS/MS and
used to construct a map containing all cleavage sites
(Figure 7B). Notably, 11 cleavage sites, distributed un-
evenly across the sequence of a2-gliadin with mostcleavages occurring in the immunogenic, PQ-rich N-ter-
minal region, were identified after only 5 min incubation.
After 60 min, 16 additional cleavage sites were detected,
again concentrated primarily in the immunogenic region
of a2-gliadin. All cleavage sites present in the 33-mer
peptide were also identified in a2-gliadin. At pH 4.5, 31
cleavage sites were identified within 5 min in a2-gliadin
(Figure 7C), with another 14 identified following more ex-
tensive digestion (Figure 7D), making for an average of
one cleavage site per 6.4 residues. Cleavage sites
were more evenly distributed across the sequence of
a2-gliadin at pH 4.5 than at pH 3.0, suggesting that
EP-B2 had lower sequence specificity at pH 4.5 than at
pH 3.0. Analogous EP-B2-catalyzed digestion of myo-
globin, a common dietary protein with lower Pro (3%)
and Gln (4%) content, revealed markedly slower degra-
dation (Figure 7E) and fewer cleavage sites (13 sites after
60 min of digestion, for an average of one cleavage site
per 11.8 residues; Figure 7F). Together these results
suggest that recombinant EP-B2 cleaves preferentially
in PQ-rich protein regions, as are present in its natural
substrates, the barley hordein proteins, and other immu-
nogenic gluten proteins that precipitate inflammation in
celiac sprue.
Since Pro and Gln are the two most abundant residues
in gluten (present at w15% and 30% abundance,
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was used to estimate the selectivity for Pro and Gln res-
idues at each subsite (P5 through P50) in a canonical EP-
B2 cleavage site (see the Supplemental Data). This anal-
ysis revealed that at both pH 3.0 and pH 4.5, Pro is
favored at the P20 and P40 positions but is disfavored
at the P10 position, while Gln is favored at the P1, P10,
and P50 positions. At pH 3.0, further preference is ex-
hibited for sites containing Pro at the P4, P3, and P2 po-
sitions. The S2 subsite, a major determinant of cysteine
endoprotease specifity [21, 26–28], does not appear to
influence strongly the selectivity of EP-B2 for Pro and
Gln, perhaps because these amino acids do not form
substantial contacts with the relatively wide S2 pocket
in EP-B2 (Figure 2E). On the other hand, selectivity for
Gln at the P1 position was observed at both pH levels
tested, consistent with results obtained for the natural
enzyme [28]. The S1 pocket of EP-B2 features a Gln at
position 68 (Figure 2E), the identity and positioning of
which distinguishes it from the otherwise close struc-
tural homolog, castor bean CysEP, which has an Asn
at the corresponding position and does not share
a strong selectivity for Gln at the substrate P1 position
[21]. Since each amino acid position is assumed to be in-
dependent of others in this analysis, recurring sequence
motifs present in a2-gliadin might cause residues that
are unimportant to EP-B2 specificity to appear signifi-
cant due to their repeated positioning proximal to pre-
ferred residues. Nonetheless, EP-B2 cleaves at 61%
(11/18) of QYXP motifs, compared to 41% (43/105) of
QYXX residues, suggesting that, minimally, the posi-
tioning of proline at P20 enhances cleavage following
glutamine, a subsite preference that is likely general to
cysteine endoproteases, given the high degree of se-
quential and structural conservation in the S0 region (Fig-
ure 2F). Remarkably, the EP-B2 consensus sequence
(QYQPXPQ) overlaps with the consensus sequence of
human transglutaminase 2 (QXP, deamidated Gln in
bold), an enzyme that plays a critical role in unmasking
the inflammatory potential of gluten peptides in celiac
sprue [47, 48]. In this issue of Chemistry & Biology, an
accompanying report from our laboratory describes
experiments that evaluate the efficacy of EP-B2 at re-
ducing the antigen burden of grocery-store gluten [49].
Significance
We have developed a heterologous bacterial expres-
sion system and a simple purification and refolding
procedure for the production of high yields (50 mg/l)
of pure, active proEP-B2, the proenzyme form of a ma-
jor barley cysteine endoprotease. This has enabled us
to ask fundamental questions about the mechanism,
kinetics, and pH dependence of proEP-B2 activation
that were previously intractable using mature enzyme
purified from natural or alternative heterologous
sources. Additionally, we have structurally and bio-
chemically characterized mature EP-B2 to evaluate
its therapeutic suitability as an enzyme supplement
for treatment of celiac sprue. We found that proEP-
B2 was rapidly autoactivated to its mature form under
acidic conditions that are similar to those found in the
stomach. Mature EP-B2 was active against the chro-
mogenic substrate, Z-Phe-Arg-pNA, over a wide rangeof acidic pH values corresponding to the conditions
found in postprandial stomach and the upper small in-
testine. EP-B2 also efficiently digested a recombinant
wheat gluten protein, a2-gliadin, as well as a highly
immunogenic and proteolytically resistant 33-mer
peptide derived from it. Strikingly, the specificity of
EP-B2 catalyzed cleavage (QYQPXPQ) was found to
overlap with the consensus sequence for human
transglutaminase 2-mediated deamidation of Gln resi-
dues in gluten proteins (QXP), an event believed to be
of critical importance in celiac sprue pathogenesis.
Our findings suggest that recombinant proEP-B2, per-
haps in conjunction with a proline endopeptidase,
may be especially well suited for celiac sprue therapy.
An accompanying report from our laboratory further
evaluates its potential as a gluten-detoxifying enzyme
therapy.
Experimental Procedures
Expression and Purification of Recombinant EP-B2
The cDNA for EPB2 (pHVEP4) was obtained as a gift from T.-H.D. Ho
(GenBank accession number: U19384) [1]. Primer-directed muta-
genesis was used to introduce a BamHI site upstream of EPB2’s
proregion, allowing for amplification of a truncated form of the
gene lacking its signal sequence. Primers used were 50-GCGGCCGT
GGATCCCTGCAGCG-30 and 50-CGATCGATCAGTGAATTC-AGTGA
CTCCCTGGCTCC-30 (restriction sites underlined). The amplified
insert was digested with BamHI and EcoRI and cloned into the ex-
pression vector, pET28b (Novagen), to yield a construct encoding
proEP-B2 with both N- and C-terminal His6 tags. The resulting plas-
mid, pMTB1, was verified by DNA sequencing and introduced into
E. coli BL21(DE3) (Novagen) via transformation. A 5 ml inoculum
was grown for 12–16 hr by shaking at 37ºC. One liter of Luria-Bertani
medium containing 50 mg/ml kanamycin was inoculated with the 5 ml
inoculum and was grown at 37ºC. At an OD600 of 0.6, expression of
recombinant proEP-B2 was induced by addition of 0.25 mM iso-
propyl b-D-thiogalactoside (Sigma). The culture was incubated at
37ºC for an additional 20 hr.
Induced cells were harvested by centrifugation at 5,000 3 g for
20 min in a J2-21M Beckman centrifuge. The cell pellet was resus-
pended in 40 ml disruption buffer (200 mM sodium phosphate [pH
7.0], 200 mM NaCl, 2.5 mM DTT, 1.5 mM benzamidine, 2.5 mM
EDTA, 2 mg/l pepstatin, 2 mg/l leupeptin, 30% (v/v) glycerol) and
lysed by sonication with a Branson Sonifier 450. Lysed cells were
centrifuged at 45,0003 g for 60 min. The proEP-B2 inclusion bodies
contained in the pellet were rinsed twice with water, and solubilized
by addition of 7 M urea, 50 mM Tris-Cl, 2 mM b-mercaptoethanol
(bMCE) (pH 8.0). The protein solution was further clarified by centri-
fugation at 45,0003 g for 60 min, and the supernatant was bound to
10 ml 1:1::Ni-NTA resin:ethanol slurry (Qiagen) for 2 hr at 4ºC. The
resin was packed into a column and washed with 7 M Urea,
50 mM Tris-Cl, and 2 mM bMCE (pH 8.0) until no protein was de-
tected in the wash by Bradford assay. The bound protein was then
eluted with 7 M Urea, 50 mM Tris-Cl, 2 mM bMCE, 200 mM imidazole
(pH 8.0). Eluted fractions containing the desired protein, as as-
sessed by SDS-PAGE, were dialyzed against 100 sample volumes
of refolding/storage buffer (100 mM Tris-Cl [pH 8.0], 5 mM EDTA,
15% (v/v) glycerol, 2 mM bMCE) at 4ºC for 3 hr, followed by a second
dialysis against a fresh portion of refolding buffer overnight. Alterna-
tively, elution fractions containing the desired protein were diluted
into refolding buffer to a final concentration of 30 mg/ml, gently agi-
tated overnight at 4ºC, and concentrated again. The final protein
concentration was determined by Bradford assay. Proenzyme prep-
arations were stored at 0ºC on ice or at 220ºC in freezer.
Substrates
The chromogenic reference substrate Z-Phe-Arg-pNA (Bachem, CA,
catalog number L-1242) was dissolved in 5% (v/v) DMSO in H2O and
was stored at220ºC. The 33-mer gluten peptide (LQLQPFPQPQLPY
PQPQLPYPQPQLPYPQPQPF) [4] was synthesized by using Boc/
Expression and Characterization of Protease EP-B2
645HBTU chemistry on solid phase as previously described [41], puri-
fied by reverse-phase HPLC, and stored at 220ºC following lyophi-
lization. For proteolytic assays, the peptide was resuspended in H2O
prior to use.
The expression and purification of recombinant a2-gliadin (Gen-
Bank accession number: AJ133612) was performed as described
[4]. Purified and lyophilized a2-gliadin was stored at 220ºC until
being dissolved in 0.1 M acetic acid for use in digestion assays. Dis-
solved a2-gliadin was stored at 0ºC on ice. Myoglobin from equine
skeletal muscle (catalog number M-0630) was purchased from
Sigma. For further details, see the Supplemental Data.
Activation of ProEP-B2
To visualize proEP-B2 activation, proEP-B2 was diluted into sodium
phosphate (pH 6.0) or sodium acetate (pH 4.5) at 1 mg/ml final
concentration at 25ºC. After a variable duration, an equal volume
of sample and Laemmli buffer/bMCE were mixed, boiled 5 min,
and analyzed via SDS-PAGE.
When determining the concentration dependence of proEP-B2
activation, 0.5–8 mM proEP-B2 was preincubated in 200 ml 250 mM
sodium citrate buffer (pH 3.0). Following preincubation at 25ºC for
varying length of time, 800 ml substrate was added to each sample
for a final concentration of 50 mM Z-Phe-Arg-pNA and 0.1–1.6 mM
preincubated proEP-B2 in 50 mM sodium citrate buffer (pH 3.0).
Reaction progress was followed by monitoring A410 with a UV/Vis
spectrometer (410 nm, 4 nm slit width; model Lambda 35, Perkin-
Elmer). The reaction rate was measured from the initial slope of
the A410 vs time plots and converted to Vo in mM/min with 3410 =
8800 M21cm21 for pNA.
Preparation of a Purified, Inhibited Mature EP-B2 Stock
for Structural Studies
EP-B2 was prepared from proEP-B2 by fully activatingw1.5 mg/ml
proEP-B2 to its mature form and then inhibiting the mature enzyme
with 10 M equivalents of the covalent cysteine protease inhibitor,
leupeptin (Acetyl-Leu-Leu-Arg-al; Sigma). Inhibited EP-B2 was puri-
fied by anion exchange chromatography, buffer exchanged into
10 mM Tris (pH 8.0) buffer, concentrated by filter centrifugation,
and stored on ice until used. For further details, see the Supplemen-
tal Data.
Crystallization and Structure Determination of Mature EP-B2
Bound to Leupeptin
Inhibited EP-B2 was crystallized by hanging-drop vapor diffusion
with 9.2 mg/ml mature EP-B2 with a reservoir of 1.36 M Li2SO4
and 0.10 M HEPES (pH 7.0). Crystals used in data collection were
cryoprotected by transfer to the reservoir solution supplemented
with 10% (v/v) glycerol and flash frozen in liquid nitrogen.
Diffraction data for the EP-B2-leupeptin complex crystal were col-
lected at the Advanced Light Source (Lawrence Berkeley National
Laboratory, Berkeley, CA) on beamline 8.3.1, and the structure of
the EP-B2-leupeptin complex was solved by homology modeling
followed by molecular replacement. The coordinates for the struc-
ture have been deposited in the Protein Data Bank (PDB code:
2FO5). For further details on crystallization, data collection and pro-
cessing, and structure solution and refinement, see the Supplemen-
tal Data.
Comparison of ProEP-B2 and EP-B2 Susceptibility to Pepsin
and Trypsin
To compare the relative susceptibility of proEP-B2 and EP-B2 to
pepsin, 0.5 mg/ml proEP-B2 or EP-B2 (both in the presence of
1 mM leupeptin, to prevent autoactivation of proEP-B2 at pH 3.0)
was incubated with pepsin (0.5 mg/ml) at pH 3.0. The reaction was
quenched at designated time points, and the digestion products
were analyzed via SDS-PAGE. Trypsin (0.5 mg/ml) digestions were
identical, except that they were performed at pH 6.0 and that leupep-
tin was not added since proEP-B2 cannot autoactivate at this pH.
pH Dependence of Proenzyme Activation and Mature
Enzyme Activity
To measure the pH optimum for the combined process, proEP-B2
was added to Z-FR-pNA at variable pH (2.3–6.9), and the rate of re-
action was measured as above. To measure the effect of pH on onlyproEP-B2 activation, proEP-B2 was preincubated at variable pH
(2.3–6.9) for 30 min at 25ºC. Thereafter, each reaction mixture was
brought to pH 6.0, Z-FR-pNA was added, and the rate of reaction
was measured as above. To measure the effect of pH on the catalytic
activity of mature EP-B2, proEP-B2 was preincubated at pH 4.5 for
60 min at 25ºC. The assay mixtures were then adjusted to pH 2.3–
6.9, Z-FR-pNA was added, and the rate of reaction was measured
as above. In all pH dependence experiments, the final concentra-
tions of enzyme and substrate were 0.4 mM and 50 mM, respectively.
For further details, see the Supplemental Data.
EP-B2 Catalyzed Proteolysis of the 33-mer Gluten Peptide
Synthetic 33-mer peptide and proEP-B2 were added at final concen-
trations of 20 mM and 2 mM, respectively, to 50 mM sodium citrate
(pH 3.0). These assay conditions were chosen because they pro-
mote rapid activation of the proenzyme and allow for catalytic activ-
ity by the mature enzyme. Control reactions contained no enzyme
but were otherwise identical. After 60 min, 100 ml of the reaction mix-
ture was injected onto a reversed-phase HPLC C18 column and
eluted with a water-acetonitrile gradient containing 0.1% (v/v) TFA.
An additional portion of reaction was quenched by boiling for
5 min and analyzed by LC-MS/MS.
EP-B2 Catalyzed Proteolysis of Recombinant a2-Gliadin
and Bovine Myoglobin
Recombinant a2-gliadin and proEP-B2 were added at final concen-
trations of 50 mM and 4 mM, respectively, to 50 mM sodium citrate
(pH 3.0) or to 50 mM sodium acetate (pH 4.5). Control reactions con-
tained no enzyme but were otherwise identical. After a variable time
period (5, 15, 30, and 60 min), a portion of the reaction mixture was
quenched by boiling and analyzed by LC-MS/MS or, alternatively,
added to an equal volume of Laemmli buffer/bMCE, boiled, and an-
alyzed by SDS-PAGE. Spectral MS2 data were searched against the
SwissProt database with the Mascot online tool (Matrix Science),
and a2-gliadin was correctly identified as the best hit. Those pep-
tides with ion scores >30 were used to construct a cleavage map,
and the frequency of each amino acid at substrate positions P5–
P50 flanking each cleavage site was tabulated and tested for signif-
icance with a statistical z test. For further details, see the Supple-
mental Data. Myoglobin digestions and cleavage site identifications
were carried out under identical conditions to the a2-gliadin diges-
tions at pH 4.5.
Supplemental Data
Supplemental data include two tables and additional Experimental
Procedures and can be found with this article online at http://
www.chembiol.com/cgi/content/full/13/6/637/DC1/.
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